Appeal No. 96-0009
Application 08/104,417
Appellants argue (brief, page 15) that their
specification (page 4, lines 11-14; page 13, lines 6-29; page
15, line 2 - page 16, line 14) shows that the recited
inhibitors are selective to the transport system and do not
bind glutamate receptors, and that the claimed method is
useful for studying the neurotransport system. Appellants
further argue (brief, page 18) that the specification (page 3,
lines 21-31; Figure 3 and Examples II-IV) shows the
specificity and effectiveness of the recited compounds in
preventing the uptake of L-glutamate away from nerve synapses
as indicated by a synaptosomal uptake assay which is well-
established in the art.
The second declaration of Dr. Bridges (paragraphs 4 and
5) presents in vivo tests on laboratory rats and in vitro
tests which show that L-trans-pyrrolidine-2,4-dicarboxylate
inhibits the transport of L-glutamate from nerve synapses.
Regarding enablement, appellants also point out that
their claimed invention is directed toward the application of
inhibitor compounds to a nerve synapse to inhibit the uptake
of the neurotransmitter away from the synapse, and is not
directed toward the treatment of any particular disease
5
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007